Daewoong Pharmaceutical: "Ollosta More Effective Than Individual Drug Combinations"

[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical announced on the 6th that it confirmed the excellent blood pressure-lowering and dyslipidemia-improving effects of ‘Ollosta,’ a combination drug of olmesartan and rosuvastatin.

Ollosta is a complex improved new drug developed using Daewoong Pharmaceutical's proprietary technology. It features an optimized drug absorption in the body by applying a patented platform technology of controlled-release bilayer tablet formulation.

This study was conducted on 154 patients requiring antihypertensive and lipid-lowering treatment. Through a 6-month follow-up comparing the Ollosta group and the group taking olmesartan and rosuvastatin as separate drugs, medication adherence and changes in blood pressure and blood lipid levels were analyzed.

The study results showed that the Ollosta group had higher medication adherence compared to the separate drug combination group. Both systolic and diastolic blood pressure tended to improve. In particular, low-density lipoprotein cholesterol (LDL-C) levels decreased to a statistically significant degree.

The study results were published in the December issue of the SCI-level international journal, the Journal of Cardiology.

This content was produced with the assistance of AI translation services.